Yahalom-Ronen Yfat, Erez Noam, Fisher Morly, Tamir Hadas, Politi Boaz, Achdout Hagit, Melamed Sharon, Glinert Itai, Weiss Shay, Cohen-Gihon Inbar, Israeli Ofir, Izak Marina, Mandelboim Michal, Caraco Yoseph, Madar-Balakirski Noa, Mechaly Adva, Shinar Eilat, Zichel Ran, Cohen Daniel, Beth-Din Adi, Zvi Anat, Marcus Hadar, Israely Tomer, Paran Nir
Department of Infectious Diseases, Israel Institute for Biological Research, Ness Ziona 7410001, Israel.
Department of Biochemistry and Molecular Genetics, Israel Institute for Biological Research, Ness Ziona 7410001, Israel.
Vaccines (Basel). 2022 Feb 14;10(2):291. doi: 10.3390/vaccines10020291.
The emergence of rapidly spreading variants of severe acute respiratory syndrome coronavirus 2 (SARS-CoV-2) poses a major challenge to the ability of vaccines and therapeutic antibodies to provide immunity. These variants contain mutations of specific amino acids that might impede vaccine efficacy. BriLife (rVSV-ΔG-spike) is a newly developed SARS-CoV-2 vaccine candidate currently in phase II clinical trials. It is based on a replication-competent vesicular stomatitis virus (VSV) platform. The rVSV-ΔG-spike contains several spontaneously acquired spike mutations that correspond to SARS-CoV-2 variants' mutations. We show that human sera from BriLife vaccinees preserve comparable neutralization titers towards alpha, gamma, and delta variants and show less than a three-fold reduction in the neutralization capacity of beta and omicron compared to the original virus. Taken together, we show that human sera from BriLife vaccinees overall maintain a neutralizing antibody response against all tested variants. We suggest that BriLife-acquired mutations may prove advantageous against future SARS-CoV-2 VOCs.
严重急性呼吸综合征冠状病毒2（SARS-CoV-2）快速传播变体的出现，对疫苗和治疗性抗体提供免疫的能力构成了重大挑战。这些变体包含特定氨基酸的突变，可能会阻碍疫苗效力。BriLife（rVSV-ΔG-刺突）是一种新开发的SARS-CoV-2候选疫苗，目前正处于II期临床试验阶段。它基于一种具有复制能力的水泡性口炎病毒（VSV）平台。rVSV-ΔG-刺突包含几个自发获得的刺突突变，这些突变与SARS-CoV-2变体的突变相对应。我们发现，接种BriLife疫苗者的血清对α、γ和δ变体保持相当的中和效价，与原始病毒相比，对β和奥密克戎变体的中和能力降低不到三倍。综上所述，我们表明，接种BriLife疫苗者的血清总体上对所有测试变体都保持中和抗体反应。我们认为，BriLife获得的突变可能对未来的SARS-CoV-2变异株具有优势。
